Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

2.

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).

Wykoff CC, Brown DM, Maldonado ME, Croft DE.

Br J Ophthalmol. 2014 Jul;98(7):951-5. doi: 10.1136/bjophthalmol-2013-304736. Epub 2014 Feb 11.

4.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

5.

Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.

Peden MC, Suñer IJ, Hammer ME, Grizzard WS.

Ophthalmology. 2015 Apr;122(4):803-8. doi: 10.1016/j.ophtha.2014.11.018. Epub 2015 Jan 14.

PMID:
25596618
6.

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.

Cho H, Shah CP, Weber M, Heier JS.

Br J Ophthalmol. 2013 Aug;97(8):1032-5. doi: 10.1136/bjophthalmol-2013-303344. Epub 2013 Jun 13.

PMID:
23766432
7.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS.

Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.

PMID:
24084500
8.

Initial utilization of aflibercept in exudative age-related macular degeneration.

Cho H, Weber ML, Shah CP, Heier JS.

Eur J Ophthalmol. 2014 Jul-Aug;24(4):576-81. doi: 10.5301/ejo.5000421. Epub 2014 Mar 17.

PMID:
24706352
9.

Aflibercept for neovascular age-related macular degeneration.

Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M, Agarwal A, Sepah YJ, Do DV, Nguyen QD.

Cochrane Database Syst Rev. 2016 Feb 8;2:CD011346. doi: 10.1002/14651858.CD011346.pub2. Review.

10.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group..

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
11.

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group..

Ophthalmology. 2013 Nov;120(11):2292-9. doi: 10.1016/j.ophtha.2013.03.046. Epub 2013 May 3.

PMID:
23642856
12.

Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.

Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K.

BMC Ophthalmol. 2016 Jul 27;16:127. doi: 10.1186/s12886-016-0305-2.

13.

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration.

Ferrone PJ, Anwar F, Naysan J, Chaudhary K, Fastenberg D, Graham K, Deramo V.

Br J Ophthalmol. 2014 Jun;98 Suppl 1:i17-21. doi: 10.1136/bjophthalmol-2013-304474. Epub 2014 May 2.

14.

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.

Monés J, Biarnés M, Trindade F, Casaroli-Marano R.

Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1737-44. doi: 10.1007/s00417-012-2009-5. Epub 2012 Apr 15.

15.

Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.

Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, Flaxel CJ, Hwang TS.

Br J Ophthalmol. 2014 Sep;98(9):1205-7. doi: 10.1136/bjophthalmol-2013-304829. Epub 2014 May 2.

PMID:
24795334
16.

Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.

Saito M, Kano M, Itagaki K, Sekiryu T.

Jpn J Ophthalmol. 2017 Jan;61(1):74-83. doi: 10.1007/s10384-016-0478-5. Epub 2016 Sep 22.

PMID:
27660164
17.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups..

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
18.

Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.

Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH.

Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):639-44. doi: 10.1007/s00417-015-3084-1. Epub 2015 Jun 20.

PMID:
26092633
19.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group..

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
20.

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P; HARBOR Study Group..

Ophthalmology. 2014 Nov;121(11):2181-92. doi: 10.1016/j.ophtha.2014.05.009. Epub 2014 Jul 9.

Supplemental Content

Support Center